C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 27.26 CNY -1.73% Market Closed
Market Cap: 72.9B CNY
Have any thoughts about
CSPC Innovation Pharmaceutical Co Ltd?
Write Note

CSPC Innovation Pharmaceutical Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSPC Innovation Pharmaceutical Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Other Long-Term Assets
ÂĄ17m
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Long-Term Assets
ÂĄ215.7m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
8%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Long-Term Assets
ÂĄ702.3m
CAGR 3-Years
24%
CAGR 5-Years
25%
CAGR 10-Years
33%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Long-Term Assets
ÂĄ928.6m
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Long-Term Assets
ÂĄ84.9m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSPC Innovation Pharmaceutical Co Ltd
Glance View

Market Cap
72.9B CNY
Industry
Pharmaceuticals

CSPC Innovation Pharmaceutical Co., Ltd., founded in 1997, has emerged as a prominent player in China's pharmaceutical landscape, with a mission to create innovative healthcare solutions. As a subsidiary of CSPC Pharmaceutical Group, the company is committed to research and development, focusing on both generic and specialty pharmaceuticals. By leveraging advanced technologies and a robust pipeline of drug candidates, CSPC Innovation has positioned itself as a pioneer in addressing critical healthcare needs in areas such as oncology, cardiovascular diseases, and infectious diseases. Investors can take note of its impressive track record in developing new drugs, attracting substantial investments through strategic partnerships and collaborations, which bolster its ability to compete in a rapidly evolving market. As the global demand for new therapies escalates, CSPC Innovation is not only positioned for growth within the domestic market but also aims for international expansion. The company's emphasis on quality and compliance with international pharmaceutical standards enhances its credibility and facilitates entry into foreign markets. With a strong balance sheet and a commitment to innovation, CSPC Innovation is poised to capture opportunities in the vast healthcare sector, making it an appealing option for investors looking to participate in the burgeoning global pharmaceutical industry. The synthesis of cutting-edge research, a dedicated workforce, and a growing portfolio of patented drugs contributes to its potential for sustainable growth, ultimately enhancing shareholder value.

Intrinsic Value
12.16 CNY
Overvaluation 55%
Intrinsic Value
Price
C

See Also

What is CSPC Innovation Pharmaceutical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
17m CNY

Based on the financial report for Sep 30, 2024, CSPC Innovation Pharmaceutical Co Ltd's Other Long-Term Assets amounts to 17m CNY.

What is CSPC Innovation Pharmaceutical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-1%

Over the last year, the Other Long-Term Assets growth was -34%. The average annual Other Long-Term Assets growth rates for CSPC Innovation Pharmaceutical Co Ltd have been -7% over the past three years , -1% over the past five years .

Back to Top